Results 151 to 160 of about 113,930 (262)

Baseline and 4‐year associations between prediabetes and kidney impairment: Insights from the ILERVAS cohort

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Prediabetes is a prevalent condition associated with increased cardiovascular and renal risk. However, the long‐term impact of haemoglobin A1c (HbA1c) within the range defined as prediabetes on kidney function remains unclear. This study aimed to evaluate the association between prediabetes and renal function (estimated glomerular ...
Aitziber Izarra, Marcelino Bermúdez‐López, José M. Valdivielso, Reinald Pamplona, Gerard Torres, Dídac Mauricio, Eva Castro‐Boqué, Elvira Fernández, Rafael Simó, Cristina Hernández, Albert Lecube, on behalf of the ILERVAS project collaborators, Eva Miquel, Marta Ortega, Ferran Barbé, Jordi de Batlle, Jessica González, Manuel Portero‐Otín, Mariona Jové, Josep Franch‐Nadal, Esmeralda Castelblanco, Pere Godoy, Montse Martinez‐ Alonso, Cristina Farràs   +23 more
wiley   +1 more source

Sustained glucagon‐like peptide‐1 receptor agonist treatment improves glycemic control and reduces all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitors: A real‐world target trial emulation in type 2 diabetes

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Background Glucagon‐like peptide 1 receptor agonists (GLP‐1 RAs) improve glycemic outcomes in people with type 2 diabetes, but their generalizability to routine clinical practice remains uncertain. Aim To evaluate the real‐world effectiveness of sustained GLP‐1 RA use on haemoglobin A1c (HbA1c) over 1 to 4.5 years, using dipeptidyl peptidase 4
Kathrine Kold Sørensen, Puriya Daniel Würtz Yazdanfard, Bochra Zareini, Hannah Karin Wood‐Kurland, Ulrik Pedersen‐Bjergaard, Mikkel Porsborg Andersen, Jens Michelsen, Henrik Imberg, Marcus Lind, Sara Hallström, Stefanie Lanzinger, Anders Munch, Johan Sebastian Ohlendorff, Thomas Alexander Gerds, Christian Torp‐Pedersen, The REDDIE Consortium   +15 more
wiley   +1 more source

Early-onset hypertension associated with a CACNA1H variant of uncertain significance: a case report and literature review. [PDF]

BMC Cardiovasc Disord
Fang X, Liu R, Zeng J.
europepmc   +1 more source

Mineralocorticoid receptor antagonists: Efficacy and safety in chronic kidney disease

Diabetes, Obesity and Metabolism, EarlyView.
Abstract The mineralocorticoid receptor (MR) has a multifaceted role in normal physiologic functions. However, research has uncovered the deleterious consequences of overactivation of the MR. It has been implicated in chronic kidney disease (CKD) via its strong association with glomerulosclerosis, interstitial fibrosis, proteinuria, and decline in ...
Amy K. Mottl, Kamlesh Khunti, Chantal Mathieu   +2 more
wiley   +1 more source

Rapid improvement of renal microcirculatory homeostasis by liraglutide following diabetes induction

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Renal microvascular dysfunction is a central driver of diabetic kidney disease, yet the potential for rapid therapeutic reversal remains obscure. We investigated the effect of short‐term liraglutide on early changes in the renal microcirculation post‐induction of diabetes.
Yuan Li, Weiqi Liu, Yingyu Wang, Bing Wang, Xiang Xu, Bingwei Li, Mingming Liu, Xu Zhang, Ruijuan Xiu   +8 more
wiley   +1 more source

Serum renin levels refine acute kidney injury prediction in critically ill children. [PDF]

Pediatr Nephrol
Pode-Shakked N, Ceschia G, Rose JE, Krallman KA, Goldstein SL, Stanski NL.   +5 more
europepmc   +1 more source

Comparison of SGLT2 Inhibitors for New‐Onset Proteinuria Risk in Patients With Type 2 Diabetes and Preserved Kidney Function

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To compare the effects of individual SGLT2 inhibitors on preventing new‐onset proteinuria in patients with type 2 diabetes and preserved kidney function. Materials and Methods A target trial emulation was performed using commercially available databases, including health checkups and claims data, between April 1, 2014 and March 31, 2023 ...
Hiroki Nobayashi, Michihiro Satoh, Takuo Hirose, Shingo Nakayama, Yutaro Iwabe, Hideaki Hashimoto, Takahisa Murakami, Kouji Okada, Takefumi Mori, Hirohito Metoki   +9 more
wiley   +1 more source

Renal PIEZO2 is an essential regulator of renin. [PDF]

Cell
Hill RZ, Nelson JW, Gyarmati G, Medrano S, Shirvan S, McCormick JA, Burquez S, Ahmed J, Eng DG, Wysocki J, Dubin AE, Servin-Vences MR, Lakshmanan A, Gomez RA, Sequeira-Lopez MLS, Shankland SJ, Batlle D, Miner JH, Peti-Peterdi J, Patapoutian A.   +19 more
europepmc   +1 more source

Cardio‐Kidney‐Metabolic Therapy Use Among Adults With Type 1 Diabetes and Chronic Kidney Disease

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Kidney and cardiovascular diseases are highly prevalent among patients with Type 1 diabetes. To date, no randomised clinical trial has reported on the impact of novel cardio‐kidney‐metabolic (CKM) therapies (GLP‐1RA and SGLT2i) on kidney function in this population.
M. Luiza Caramori, Enrico Repetto, Christopher Perkins, Ambarish Pandey, Peter Rossing   +4 more
wiley   +1 more source

Risk of Hypertension and Chronic Kidney Disease Following Aldosterone Dysregulation. [PDF]

Am J Hypertens
Townsend RR, Agiro A, Luan S, Brzozowski K, Moyneur E, Tetreault-Langlois P, Huang J.   +6 more
europepmc   +1 more source